TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

This study has been completed.

Study NCT00254046 Information provided by Tibotec Pharmaceuticals, Ireland

First Received: November 10, 2005 Last Updated: November 9, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	July 2008
Primary Completion Date:	February 2007 (Final data collection date for primary outcome measure)